Genor Biopharma Holdings Limited
嘉和生物藥業(開曼)控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6998)

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2022

The board (the "**Board**") of directors (the "**Directors**") of Genor Biopharma Holdings Limited (the "**Company**", and together with its subsidiaries, the "**Group**") is pleased to announce the audited consolidated results of the Group for the year ended 31 December 2022 (the "**Reporting Period**"), together with the comparative figures for the year ended 31 December 2021. The consolidated financial statements of the Group for the Reporting Period have been reviewed by the Audit Committee of the Company and audited by the Company's auditor.

In this announcement, "we", "us" and "our" refer to the Company and where the context otherwise requires, the Group.

FINANCIAL HIGHLIGHTS

- **Total revenue** was RMB15.9 million for the Reporting Period, primarily generated by (i) drug sales of Jiayoujian 佳佑健® (GB242, Infliximab Biosimilar), and (ii) providing research and manufacturing services to our customers under fee-for-service contracts.

- **Research and development expenses** were RMB583.9 million for the Reporting Period, as compared with RMB612.7 million for the year ended 31 December 2021. The spending was mainly attributable to (i) our new drugs development fee and ongoing clinical trials expenses and (ii) our employee salary and related benefit costs. The decrease was mainly due to the decrease in employee benefits expenses.

- **Total comprehensive loss** was RMB731.8 million for the Reporting Period, as compared with RMB865.8 million for the year ended 31 December 2021. The decrease was primarily due to (i) decrease in expenses and (ii) total revenue generated for the Reporting Period.

- Under **Non-HKFRS measures**, our adjusted loss(1) was RMB682.2 million for the Reporting Period, as compared with RMB731.1 million for the year ended 31 December 2021.

(1) Adjusted loss is calculated as loss for the years of 2022 and 2021 excluding share-based payment expenses. For details of the reconciliation of the loss for the Reporting Period to the adjusted loss of the Group, please refer to the section headed "Financial Review" in this announcement.

BUSINESS HIGHLIGHTS

During the Reporting Period, we have continued to make remarkable progress in the development of our drug candidates in pipeline and business operations, including the following major milestones for our pipeline products and corporate achievements:

GB491 (Lerociclib) – a CDK4/6 inhibitor with better efficacy and tolerance for breast cancer patients

- In January 2022, the first patient was dosed in a phase III clinical trial of GB491 (Lerociclib) in combination with Letrozole in first line HR+/HER2 – advanced breast cancer.

- Phase III clinical trial for the second-line has completed patient enrolment.

- Phase III clinical trial for the first-line is progressing rapidly as planned.

GB261 (CD20/CD3, BsAb) – potential BIC CD20/CD3 bi-specific antibodies

- Several clinical centers have been opened in Australia and China.

- We observed efficacy in the FIH clinical trial in Australia in the dose escalation up to 3mg with preliminary clinical POC data, which were consistent with the molecular design mechanism of GB261, indicating a good safety, pharmacokinetic profile and clinical antitumor activities. As at the date of this announcement, a high-dose escalation is in progress.

- On 23 May 2022, implied permission was obtained from the NMPA for the phase I/II clinical trial of GB261 (CD20/CD3, BsAb) for the treatment of patients with relapsed or refractory B-cell non-Hodgkin Lymphoma (B-NHL) and Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL).

- On 8 September 2022, the first patient was dosed in the phase I/II clinical trial of GB261(CD20/CD3, BsAb) in China.

GB263T (EGFR/cMET/cMET, TsAb)

- On 28 March 2022, the FIH clinical trial application for GB263T (EGFR/cMET/cMET, TsAb) was approved by Bellberry HREC in Australia to treat advanced NSCLC.

- On 18 May 2022, the first patient was dosed in the FIH clinical trial of GB263T (EGFR/ cMET/cMET, TsAb).

- On 2 June 2022, phase I/II clinical trials of GB263T (EGFR/cMET/cMET, TsAb) were approved by NMPA to treat advanced NSCLC.

- On 14 October 2022, the first patient was dosed in the phase I/II clinical trials of GB263T (EGFR/cMET/cMET, TsAb). As at the date of this announcement, a high-dose escalation is in progress.

GB492 (IMSA101)

- In January 2022, GB492 (IMSA101) was approved by the CDE to conduct the dose escalation research of GB492 (IMSA101) with PD-1 in subjects with advanced refractory malignancies, and the 400ug monotherapy dose group escalation of clinical trial was completed.

- The clinical trial of the new drug combining GB492 (IMSA101) with Aibining® (GB226, Geptanolimab) was approved by the Human Genetic Resources Administration Office of the PRC.

Strategic Cooperation and Commercialization

Cooperative Development Agreement with Abogen

- In May 2022, the Company entered into a cooperative development agreement with Abogen to jointly develop globally innovative mRNA products and related pharmaceuticals, and research and develop mRNA drugs for tumor treatment. As at the date of this announcement, the project is in good progress, and one of the cooperation projects is in the pre-clinical candidate compounds (pcc) stage.

Jiayoujian 佳佑健® (GB242, Infliximab Biosimilar)

- On 23 February 2022, we obtained approval from the NMPA for the launch of Jiayoujian 佳佑健® (GB242, Infliximab Biosimilar) in the treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriasis, Adult Ulcerative Colitis, Adult and over 6 years old Pediatric Crohn's Disease, and Fistulising Crohn's Disease.

- During the Reporting Period, Jiayoujian 佳佑健® (GB242, Infliximab Biosimilar) has been made available for online procurement in 17 provinces and cities across China, and the sales amount has reached approximately RMB11.9 million.

New Drugs Research and Development

- The R&D team of the Company focused on developing targeted antibodies and projects with FIC potential, and continued to promote the research and development platform for discovering FIC/BIC potential T-cell Engager, bi-specific/multi-specific antibodies in immuneoncology and BsADC.

- As of December 31, 2022, five FIC/BIC bi-specific/multi-specific antibody projects were carried out and nearly 10 differentiated innovation projects involving different molecular forms were in the early stage of research and development.

Chemistry, Manufacturing and Controls (CMC)

- The Company continued to promote efficient innovation and development in technology, research and development, processes, management and other areas.

- In addition to solving the industry pain points such as low heterologous pairing rate, high polymer content, removal of homodimer impurities, unstable intermediates, difficulty in activity analysis methods and difficulty in the development of formulations, especially high-concentration formulations, the CMC team of the Company also demonstrated industry-leading strength and rapid execution in the process technology development of GB261 (CD20/CD3, BsAb), GB263T (EGFR/cMET/cMET, TsAb) and other products.

RECENT DEVELOPMENT AFTER THE REPORTING PERIOD

We continued to make significant progress in our drug pipeline and business operations after the Reporting Period, including the following major milestones and achievements:

GB491 (Lerociclib)

- Phase III clinical trial of GB491 (Lerociclib) for the first line HR+/HER2- advanced breast cancer has completed patient enrolment.

- The China National Medical Products Administration ("**NMPA**") has officially accepted the new drug application for GB491 (Lerociclib) in combination with Fluvestran as the treatment of HR+/HER2- locally advanced or metastatic breast cancer patients with disease progression following previous endocrine therapy on 28 March 2023.

Jiayoujian 佳佑健® (GB242, Infliximab Biosimilar)

- Jiayoujian 佳佑健® (GB242, Infliximab Biosimilar) has been made available for online procurement in 22 cities and provinces across China.

OUR MISSION

Our mission is to become a biopharmaceutical engine in discovery, research, development, manufacturing and commercialisation of innovative therapeutics initially for patients in China and gradually for patients globally.

OVERVIEW

Founded in 2007, the Group has been striving to "provide innovative therapeutics initially for patients in China and gradually for patients globally". The Company is committed to creating an innovative, platform-based and integrated company capable of drugs innovation, research and development, pre-clinical study, clinical development, registration, Chemistry, Manufacturing and Control ("**CMC**") development and commercialized manufacturing based in China, with global reach.

Faced with multiple changes in the biomedical industry in 2022, the Company welcomed challenges, realized stable development and achieved opportunities following the strategy of "focus, optimization, acceleration". It always strategically focuses on therapeutic areas with substantial unmet medical needs in oncology, autoimmune and other diseases. The Company implemented efficient operation in the early-stage research and development, CMC, clinic and production.

In terms of early-stage research and development, the Company has successfully established the research and development platform for global first-in-class ("**FIC**")/differential T-cell Engager, bi-specific/multi-specific antibodies in immune-oncology and Bispecific Antibody Drug Conjugates ("**BsADC**"), focusing on molecules with potential to be the global FIC and best-in-class ("**BIC**") products featuring with the best potential to become clinically beneficial and commercially viable drugs.

With the aim of rapid promotion of investigational new drug ("**IND**") applications and clinical trials, the new drug R&D team carried out adequate evaluation and research on the pre-clinical pharmacology toxicology for IND applications; the CMC team of the Company constantly optimized the technological advantages of process development; the clinical R&D team and top-grade clinical experts cooperated to formulate the clinical development strategy for the maximum product value and scientific and comprehensive clinical trial proposal to promote the implementation of clinical trials in an efficient and high-quality manner; the Registration Affairs Department cooperated with various functional departments to efficiently prepare the IND application materials in accordance with the regulatory requirements in China and Australia, and maintained close communication with drug regulatory authorities and review agencies, which laid solid foundation for the optimization of clinical trial design and acceleration of application and approval.

The in-depth perception of product science, mechanisms and features by each department subordinate to the Company, efficient, professional, thorough and complete preparations and close cooperation across different departments contributed to the rapid celebration of clinical trials. In 2022, several of our clinical trials – GB491 (Lerociclib), GB261 (CD20/CD3, BsAb) and GB263T (EGFR/cMET/cMET, TsAb) achieved rapid progress in a rate higher than the industrial level despite the great difficulties brought forth by the pandemic in various regions. We are pleased to note that the NMPA has officially accepted the new drug application for GB491 (Lerociclib) in combination with Fluvestran as the treatment of HR+/HER2- locally advanced or metastatic breast cancer patients with disease progression following previous endocrine therapy. We hope provide this safer and effective CDK4/6 inhibitor as a meaningful new treatment option to Chinese breast cancer patients soon.

Through paralleled efforts in origin innovation and strategic cooperation, the Company is committed to developing its global innovation and actively expanding external cooperation in various aspects such as early-stage research and development and commercialization. In terms of early-stage research and development, we entered into strategic cooperation with enterprises with the technical platform advantages including Suzhou Abogen Biosciences Co., Ltd ("**Abogen**") to complement each other and jointly promote the discovery and development of mRNA drugs for tumor treatment with great potential. In terms of commercialization, our Jiayoujian 佳佑健® (GB242, Infliximab Biosimilar) obtained approval from the NMPA, which provided another treatment choice for patients suffering from 6+1 indications of Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriasis, Adult Ulcerative Colitis, Adult and over 6 years old Pediatric Crohn's Disease, and Fistulising Crohn's Disease.

The shareholders of the Company possess abundant resources and industry expertise, including global and Chinese biotechnology-focused specialist funds and biopharma platforms experienced in supporting and developing biopharmaceutical companies. The core management team members of the Group have more than 20 years of industry experience on average with a proven track record and a well-balanced combination of expertise spanning research and discovery, clinical development, manufacturing, registration affairs and financing.

With a clear objective and strategy, the passion and motivation to tackle difficulties and its profound expertise accumulated, combined with the internationally advanced process development capability, pre-clinical and clinical drugs manufacturing capability, improved analysis and test capability, comprehensive quality control system and commercial production capability, the Company achieved rapid progress in key projects during the Reporting Period, which not only allowed it to become an industry leader in many areas, but also laid a solid foundation for the consequent achievements.

THE GROUP'S DRUG CANDIDATES

As at the date of this announcement, the Group has built up rich innovative drug candidates pipelines. Relying on the highly specialised departments and the close collaboration between different departments, the Company accelerates the application for clinical trials of pipeline innovative drugs and rapidly advances clinical progress, including focusing on Chinese and Asia Pacific products.

- Phase 3 clinical trial for the second line breast cancer indication of GB491 (Lerociclib) has completed patient enrolment.

- Phase 3 clinical trial for the first line breast cancer indication of GB491 (Lerociclib) is progressing rapidly as planned.

Focusing on the strategic direction of global innovation, the Group focuses on the research and development of innovative drugs with the potential FIC/BIC. Fueled by the strong antibody discovery platform of the Company:

- Two highly differentiated bi-specific/multi-specific antibody drugs, namely GB261 (CD20/CD3, BsAb) and GB263T (EGFR/cMET/cMET, TsAb) have made breakthroughs and are progressing rapidly. Both drugs have been dosed to patients in FIH clinical trials in Australia and Phase I/II clinical trials approved by the NMPA in China, and are advancing rapidly.

- Five FIC/BIC bi-specific/multi-specific antibody projects were carried out and nearly 10 differentiated innovation projects involving different molecular forms were in the early stage of research and development.

- The new drug application ("**NDA**") of Aibining 艾比寧® (GB226, Geptanolimab) was under technical review.

Jiayoujian® 佳佑健® (GB242, Infliximab Biosimilar) was officially approved for marketing by NMPA on 23 February 2022 for the treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriasis, Adult Ulcerative Colitis, Adult and Pediatric Crohn's Disease and Fistulising Crohn's Disease. As at 31 December 2022, Jiayoujian® 佳佑健® (GB242, Infliximab Biosimilar) has been made available for online procurement in 17 provinces and cities across China, and the sales amount reached approximately RMB11.9 million.

PRODUCT PIPELINE

The following chart shows our robust pipeline of drug candidates that are currently under development in China and worldwide across various therapeutic areas and the development status of antibody drug candidates in clinical stage as at the date of this announcement:

Product	Target/MoA (reference drug)	Indication	Classification	Commercial Rights	Discovery	Pre – Clinical	IND	Phase 1	Phase 2	Phase 3	NDA Review
GB491 (Lerociclib)	CDK4/6+AI (combo w/ letrozole)	1L HR+/HER2- BC	Novel (In-license)	APAC ex-JP (1)							
	CDK4/6+SERD (combo w/ fulvestrant)	2L HR+/HER2- BC									
	CDK4/6+ EGFR (combo w/ osimertinib)	EGFR-Mutant NSCLC									
GB261	CD20 x CD3	NHL	Novel (In-house)	Worldwide							
GB263T	EGFRxc-Metxc-Met	NSCLC	Novel (In-house)	Worldwide							
GB242 (Infliximab)	TNF-α (infliximab)	RA, AS, Ps, CD, UC	Biosimilar (In-house)	Worldwide							
GB226 (Geptanolimab)	PD-1	r/r PTCL	Novel (In-license)	China							
		2L+ Cervical Cancer									
		ASPS									
		r/r PMBCL									
	PD-1+VEGFR (combo w/ fruquintinib)	2L/3L+ EGFR+ NSCLC									
		2L+ mCRC									
GB492 (IMSA101)	PD-1 (combo w/ GB226*^)+STING	Solid Tumours	Novel (In-license)	APAC ex-JP (2)							
GB221 (Coprelotamab)	HER2	HER2+ 1L/2L+ mBC	Novel (In-house)	Worldwide							
GB223	RANKL	GCTB, PMO	Novel (Co-develop)	Worldwide							
GB241 (Rituximab)	CD20 (rituximab)	1L DLBCL	Biosimilar (In-house)	Co-development							
GB251	HER2 ADC	HER2+ 1L/2L+ mBC	Novel (Co-develop)	Worldwide							
GB262	PD-L1 x CD55	Cancers	Novel (In-house)	Worldwide							
GB264	Claudin 18.2 x CD3	GI Cancers	Novel (In-house)	Worldwide							
GB266	PD-L1xLAG3xLAG3	Cancers	Novel (In-house)	Worldwide							
GB267	Undisclosed	Cancers	Novel (In-house)	Worldwide							
***	Undisclosed	Cancers	Novel (In-house)	Worldwide							



Notes:
(1) Clinical trials are sponsored by G1 Therapeutics, Inc. (Nasdaq: GTHX) ("G1 Therapeutics").
(2) Clinical trials are sponsored by ImmuneSensor Therapeutics.
* Five undisclosed candidates are under discovery phase

BUSINESS REVIEW

During the Reporting Period, we have continued to make remarkable progress in the development of our drug candidates in pipeline and business operations, including the following major milestones for our pipeline products and corporate achievements:

1. Events during the Reporting Period

Research and Development of the Global Innovative New Drugs

The R&D team of the Company focused on developing targets and projects with FIC potential, and continued to promote the global research and development platform for FIC/BIC potential T-cell Engager, bi-specific/multi-specific antibodies and BsADC in immune-oncology.

As at 31 December 2022,

- Five FIC/BIC bi-specific/multi-specific antibody projects were carried out.

- Nearly 10 differentiated innovation projects involving different molecular forms were in the early stage of research and development.

Continuous Promotion of the Establishment of CMC Platform

The CMC team of the Company continued to promote the platform-based construction of internal and external workflow of the project, and practiced the "focus and optimization" strategy of the Company.

- Through the domestic exploration of culture medium, chromatographic filler, disposable products (dispensing bags, storage bags, filling bags and filters) and auxiliary materials, we, without the prejudice against the quantity and quality of products, significantly reduced production costs, improved the stability of the supply chain, reduced storage costs, and enhanced liquidity efficiency.

- We continued to promote the establishment and optimization of a molecular developable assessment platform for rapid protein expression, high-throughput purification, full range of characterization and process applicability assessment. We facilitated the development and application of high-concentration preparation development platform in line with the demand of projects.

- We further improved the quality control and study platform. We strengthened the construction of applicable quality system and MAH-related quality system and initiated the establishment of the drug variety archive.

Accelerated Registration and Clinical Trials

During the Reporting Period, the Company achieved rapid application, approval and promotion of clinical trials of product pipelines in China and Australia. Such rapid advancement in clinical trials was attributable to the high specialization of and close cooperation across departments:

- Based on in-depth perception of product science, mechanisms and features, the Group developed the registration and clinical development strategies, and continuously enhanced communication with industry leaders in relevant treatment fields, drug regulatory authorities, review agencies, and clinical research centers.

- Relying on plentiful experience and extensive resources, the Group carried out the layout and establishment of the research centre, project initiating and management, selection and recruitment of, and the entering of agreements with patients and subjects in an efficient and quality manner.

- **CMC Process Technology R&D Centre** fully supported the advancement of projects at different stages. It promoted and completed the validation of API process for the project at late clinical stage (i.e. GB491 (Lerociclib)), and initiated the validation of the preparation process and packaging of such project; and facilitated the preparation of relevant research and data for approval of IND projects (i.e. GB261 (CD20/CD3, BsAb) and GB263T (EGFR/cMET/cMET, TsAb)) with clinical approvals successfully obtained. Moreover, it facilitated the development of early research projects to IND.

During the Reporting Period, three IND/Clinical Trials Notification ("**CTN**") approvals were quickly granted to our core products including GB261(CD20/CD3, BsAb) IND, GB261(CD20/CD3, BsAb) CTN, and GB263T(EGFR/cMET/cMET, TsAb) IND.

During and after the Reporting Period, we continued our efforts in promoting the clinical pipelines development and achieved milestones as follows:

1) Two Phase III trials of GB491 (Lerociclib) completed patient enrolment. The NMPA has officially accepted the new drug application for GB491 (Lerociclib) in combination with Fluvestran as the treatment of HR+/HER2- locally advanced or metastatic breast cancer patients with disease progression following previous endocrine therapy on 28 March 2023.

2) GB261 (CD20/CD3, BsAb) obtained the preliminary clinical Proof of Concept ("**POC**") data, and is in the process of high dose escalation; Phase I/II clinical trials have achieved first patient dosed in China.

3) GB263T (EGFR/cMET/cMET, TsAb) was approved by the Bellberry Human Research Ethics Committee ("**Bellberry HREC**") for the first first-in-human ("**FIH**") clinical trial in Australia and approved by the NMPA for Phase I/II clinical trials in China, and the first patient was dosed.

4) GB226-008 pivotal Phase II trial enrolment was completed.

5) The monotherapy clinical trial of dose escalation up to 400ug of GB492(IMSA101) was completed.

6) GB221-004 Phase III clinical trial was enrolled to complete 12 months of treatment.

GB491 (Lerociclib) – a CDK4/6 inhibitor which is developed for breast cancer patients with better safety and excellent efficacy

GB491 (Lerociclib), is a novel, potent, selective oral bioavailable CDK4/6 inhibitor co-developed by the Group and G1 Therapeutics, for use in combination with endocrine therapy in advanced breast cancer.

Based on the data published at European Society for Medical Oncology (ESMO) 2020 conference, GB491 (Lerociclib) has demonstrated a better safety and tolerability profile, enabling uninterrupted daily dosing and better long-term benefits, and could potentially be a BIC CDK4/6 drug candidate.

Patient enrolment of the Phase III trials for both first and second line has been completed quickly via adaptive and seamless experiment design, scientific reference and data bridging, seamless registration strategy, and excellent execution.

In January 2022, the first patient of Phase III clinical trials of GB491 (Lerociclib) in combination with Letrozole in first line treatment of HR+/HER2 – advanced breast cancer was dosed. As at the date of this announcement, the clinical trials for both second line and first line have completed patient enrolment.

NMPA has officially accepted the new drug application for GB491 (Lerociclib) in combination with Fluvestran as the treatment of HR+/HER2- locally advanced or metastatic breast cancer patients with disease progression following previous endocrine therapy on 28 March 2023.

GB261 (CD20/CD3, BsAb)

GB261 (CD20/CD3, BsAb) is the first T-cell engager with low affinity to bind CD3 and has Fc functions (ADCC and CDC). GB261 (CD20/CD3, BsAb) significantly inhibits rituximab-resistant cancer cell proliferation in both in vitro assays and in vivo models; meanwhile with T-cell activation, GB261 (CD20/CD3, BsAb) induces less cytokine release compared with compound in the same class. Thus, GB261 (CD20/CD3, BsAb) is a highly potent bispecific therapeutic antibody for B cell malignancies. It has potential to be a better and safer T-cell engager with competitive advantages over other CD3/CD20 agents.

GB261 (CD20/CD3, BsAb) has opened more than a dozen clinical centres in Australia and China. We obtained the preliminary clinical POC data in the FIH clinical trial of GB261 (CD20/CD3, BsAb) in Australia in the process of a dose escalation up to 3mg, which were consistent with the molecular design mechanism of GB261 (CD20/CD3, BsAb), indicating a good safety, pharmacokinetic profile and clinical antitumor activities. The high-dose group is currently in dose escalation.

In China, GB261 (CD20/CD3, BsAb) obtained the implied license for Phase I/II clinical trials from the NMPA on 23 May 2022 for the treatment of patients with recurrent or refractory B-cell non-Hodgkin Lymphoma (B-NHL) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

On 8 September 2022, GB261 (CD20/CD3, BsAb) Phase I/II clinical trials achieved first patient dosing in China.

GB263T (EGFR/cMET/cMET, TsAb)

GB263T (EGFR/cMET/cMET, TsAb) was the first tri-specific antibody of EGFR/cMET/cMET in the world, targeting EGFR and two different cMET epitopes, so designed to enhance its safety and efficacy. With highly differentiated design, GB263T (EGFR/cMET/cMET, TsAb) exhibits multiple mechanisms of action to inhibit primary and secondary EGFR mutations and cMET signaling pathway simultaneously.

In pre-clinical studies, GB263T (EGFR/cMET/cMET, TsAb) effectively thwarted ligand-induced phosphorylation of EGFR and c-MET compared to its Amivantamab (JNJ-372) analogue, and demonstrated better dual inhibition of EGFR and cMET signaling pathways. Meanwhile, GB263T (EGFR/cMET/cMET, TsAb) effectively induced the endocytosis of EGFR and cMET, and significantly reduced the protein expression levels of EGFR and cMET. GB263T (EGFR/cMET/cMET, TsAb) played a significant dosage-dependent role in tumor suppression in several different tumor models including EGFR exon 20 insertions, EGFR exon 19 deletions, C797S mutations and various cMET expression abnormalities. In toxicology studies in cynomolgus monkeys, no significant toxic side effects were observed after 4 weeks of observation, even in the highly-dosed group.

The Bellberry HREC approval for the FIH clinical trial of GB263T (EGFR/cMET/cMET, TsAb) was obtained in Australia on 28 March 2022 for the treatment of patients with advanced non-small cell lung cancer ("**NSCLC**"), with the first patient dosed on 18 May 2022.

In China, the clinical trial application for GB263T (EGFR/cMET/cMET, TsAb) was approved by the NMPA on 2 June 2022 to commence phase I/II clinical trials, with the first patient dosed on 14 October 2022 in China for the treatment of patients with advanced NSCLC. As at the date of this announcement, the high-dose group is currently in dose escalation.

GB492 (IMSA101) – potential Best in Class STING agonist

GB492 (IMSA101) is the major mediator of innate immune sensing of cancerous cells, which the Group exclusively licensed from ImmuneSensor Therapeutic in June 2020. STING agonist, as an immune stimulatory therapy, may further increase the response of immune checkpoint inhibitors for patients. Multiple studies have shown that STING agonists can activate the cGAS-STING signaling and significantly enhance the efficacy of cancer immunity cycle when using in combination with other immune checkpoint inhibitors (ICI), which may become a potential FIC therapy.

For phase I/II clinical trial of GB492 (IMSA101) as a monotherapy or in combination with Aibining®艾比寧® (GB226, Geptanolimab) in patients with advanced/treatment-refractory malignancies:

- In January 2022, we finished monotherapy clinical trials.

- In January 2022, we obtained approval from Center for Drug Evaluation ("**CDE**") to directly conduct a dose-escalating study of GB492 (IMSA101) in combination with PD-1 in patients with advanced malignancy, based on the available data on 400ug dose group in the monotherapy study in China and all data of the monotherapy dose-escalation study in the United States. In this clinical trial, an innovative FIH trial design was employed to combine the dose escalations when GB492 is administered alone and when it is administered with Aibining®艾比寧® (GB226, Geptanolimab). It is the first STING agonist combination therapy that has obtained clinical trial approval in China.

- Further exploration of combination therapy will be conducted based on global data.

Aibining®艾比寧® (GB226, Geptanolimab)

In January 2022, Gxplore-008, as a phase II pivotal clinical study evaluating Aibining® 艾比寧® (GB226, Geptanolimab) in recurrent or metastatic cervical cancer patients with PD-L1 positive status, who failed in platinum-based chemotherapy, completed the last subject enrolment.

The NDA of Aibining®艾比寧® (GB226, Geptanolimab) as a monotherapy for relapsed/refractory peripheral T-cell Lyphoma (r/r PTCL) is under technical review.

GB221 (Her2, monoclonal antibody)

In April 2022, the last patient in GB221-004, a randomized, double-blind, multi-center phase III clinical study evaluating GB221 (Her2, monoclonal antibody) or trastuzumab in combination with docetaxel in patients with HER2+mBC in the first-line setting, was enrolled to complete 12 months of treatment.

GB241 (Rituximab Biosimilar)

During the Reporting Period, we completed the phase III clinical trial with Nanjing Yoko Pharmaceutical Group Co. Ltd. for the treatment of B-cell lymphoma with GB241 (Rituximab Biosimilar) in China.

Strategic Cooperation and Commercialization

In May 2022, the Company entered into a cooperative development agreement with Abogen to jointly develop globally innovative mRNA products and related pharmaceuticals. The Group's antibody development platform will be integrated with Abogen's mRNA technology platform to enable them to jointly research and develop mRNA drugs for tumor treatment and are progressing smoothly. One of the collaborative projects is in the pre-pcc stage.

As at the date of this announcement, the Group is exploring opportunities to conduct cooperative development projects with various innovative technology platforms.

Commercialization–Jiayoujian 佳佑健® (GB242, Infliximab Biosimilar) has been approved for commercialization

On 23 February 2022 the NMPA has granted marketing approval for Jiayoujian 佳佑健® (GB242, Infliximab Biosimilar) which is used for the treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriasis, Adult Ulcerative Colitis, Adult and Pediatric (aged above 6 years old) Crohn's Disease and Fistulising Crohn's Disease.

During the Reporting Period, Jiayoujian 佳佑健® (GB242, Infliximab Biosimilar) has been made available for online procurement in 17 provinces and cities across China, the sales amount has reached approximately RMB11.9 million.

2. Events after the Reporting Period

GB491 (Lerociclib)

- Phase III clinical trial of GB491 (Lerociclib) for the first line HR+/HER2- advanced breast cancer has completed patient enrolment.

- The China National Medical Products Administration (NMPA) has officially accepted the new drug application for GB491 (Lerociclib) in combination with Fluvestran as the treatment of HR+/HER2- locally advanced or metastatic breast cancer patients with disease progression following previous endocrine therapy on 28 March 2023.

Jiayoujian 佳佑健® (GB242, Infliximab Biosimilar)

- Jiayoujian 佳佑健® (GB242, Infliximab Biosimilar) has been made available for online procurement in 22 provinces and cities across China.

Cautionary Statement required by Rule 18A.08(3) of the Listing Rules: Apart from Jiayoujian 佳佑健® (GB242, Infliximab Biosimilar), the Company cannot guarantee that it will be able to develop, and ultimately market, any of the other drug candidates successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

BUSINESS OUTLOOK

The Group strives to build an innovative, platform-based and integrated company capable of drugs innovation, research and development, pre-clinical study, clinical development, registration, CMC development and commercialized manufacturing.

To achieve this mission, the Group will continue to concentrate its efforts on potential global FIC and BIC innovation pipelines, and maximize its existing product portfolio by developing and executing a comprehensive strategy to conduct research on moleculars with the best potential to become clinically beneficial and commercially viable drugs, and to address unmet medical needs in China and globally.

Specifically, the Company will continue to focus on promoting key projects and exploration of FIC potential in multi-dimensions to achieve an effective balance between efficiency and cost based on the in-depth understanding of target molecular biology, cell biology and immunological mechanisms. Through cooperative research and development and open innovation, the Company is actively exploring cooperation projects between its platform for early discovery of highly differential T-cell Engager, bi-specific/multi-specific antibodies in immune-oncology, BsADC, and different innovative technology platforms to further promote global innovation through cooperation.

The Company will further expand its strategic cooperation with a focus on efficient, premium and original innovation, and actively explore collaboration with different forms of advanced technologies. In addition to bi-specific and multi-specific antibodies, we will initiate more early-stage research and development projects which are highly differentiated in multi-dimensions.

Other than concentration and optimization, we will continuously seek the acceleration of clinical advancement and diversification of market expansion. The Company plans to submit the NDA application to the NMPA in the next 18 months depending on the results of the phase III clinical trial of GB491 (Lerociclib) in the first line HR+/HER2-breast cancer and to achieve the approval of the new drug application for GB491 (Lerociclib) in combination with Fluvestran as the treatment of HR+/HER2- locally advanced or metastatic breast cancer patients with disease progression following previous endocrine therapy. We remain committed to addressing the large market of breast cancer in China and around the world with a safe, effective and well tolerated novel therapy.

As for bi-specific and tri-specific antibody drug candidates, the Company will continue to accelerate the development of clinical trials in Australia and China. GB261 (CD20/CD3, BsAb) is scheduled to complete its phase I/II clinical trials within the next 12-18 months. The clinical trial of GB263T (EGFR/cMET/cMET, TsAb) will continue to progress rapidly, with preliminary clinical data to validate POC planned within the next 12 months.

On the basis of the global POC data for GB261 (CD20/CD3, BsAb) and GB263T (EGFR/cMET/cMET, TsAb), the Company will actively expand external partnership in our clinical programs.

In addition, the Company will continuously seek approval for Aibining®艾比寧® (GB226, Geptanolimab) in relapsed or refractory peripheral T-cell lymphoma (PTCL) and other indications and exploring potential of new combination therapy, further advancing the phase I clinical trial and POC of Aibining®艾比寧® (GB226, Geptanolimab) with GB492 (IMSA101).

FINANCIAL REVIEW

The Reporting Period compared to year ended 31 December 2021

	Notes	Year ended 31 December	
		2022	2021
		RMB'000	*RMB'000*
Revenue	2	**15,932**	–
Cost of revenue	3	**(983)**	–
Gross profit		**14,949**	–
Selling expenses	4	**(83,143)**	(98,603)
Administrative expenses	5	**(134,130)**	(207,350)
Research and development expenses	6	**(583,881)**	(612,718)
Other income – net	7	**9,855**	44,813
Other (losses)/gains – net		**(6,369)**	14,751
Operating losses		**(782,719)**	(859,107)
Finance income	8	**53,314**	23,729
Finance costs	8	**(3,015)**	(30,928)
Finance income/(costs) – net		**50,299**	(7,199)
Loss before income tax		**(732,420)**	(866,306)
Income tax credit		**2,024**	932
Loss for the Reporting Period	9	**(730,396)**	(865,374)

1. Overview

During the Reporting Period, the revenue of the Group was RMB15.9 million, as compared to nil for the year ended 31 December 2021, and the loss for the Reporting Period were RMB730.4 million, as compared to a loss of RMB865.4 million for the year ended 31 December 2021.

Research and development expenses of the Group were RMB583.9 million for the Reporting Period, as compared to RMB612.7 million for the year ended 31 December 2021. Administrative expenses were RMB134.1 million for the Reporting Period, as compared to RMB207.4 million for the year ended 31 December 2021. Selling expenses of the Group were RMB83.1 million for the Reporting Period, as compared to RMB98.6 million for the year ended 31 December 2021.

2. Revenue

Revenue for the Reporting Period was RMB15.9 million, primarily generated by (i) drug sales of Jiayoujian 佳佑健® (GB242, Infliximab Biosimilar) and (ii) providing research and manufacturing services to our customers under fee-for-service contracts. Revenue for the year ended 31 December 2021 was nil.

3. Cost of Revenue

Cost of revenue for the Reporting Period was RMB1.0 million, as compared to nil for the year ended 31 December 2021. This change is primary due to the increase of revenue. Since the drug substance of the Jiayoujian 佳佑健® (GB242, Infliximab Biosimilar) sold this year was manufactured in 2021, before we got the marketing approval from the NMPA, the related spending was recorded as research and development expenses in 2021 as well.

4. Selling Expenses

Selling expenses decreased by 15.7% from RMB98.6 million in 2021 to RMB83.1 million in 2022, primarily due to the decrease in employee benefits expenses for commercial personnel.

5. Administrative Expenses

Administrative expenses decreased by 35.3% from RMB207.4 million in 2021 to RMB134.1 million in 2022, primarily due to the decrease in our employee benefit expenses, mainly employee share-based payment expenses for managerial and administrative personnel.

6. Research and Development Expenses

Research and development expenses decreased by 4.7% from RMB612.7 million in 2021 to RMB583.9 million in 2022, primarily due to the decrease in employee benefits expenses for research and development personnel.

The following table summarises the components of the research and development expenses of the Group for the years ended 31 December 2022 and 2021:

	Year ended 31 December	
	2022	2021
	RMB'000	*RMB'000*
Development fee and clinical trial expenses	**239,733**	236,282
Employee benefits expenses	**185,668**	223,688
Raw material and consumables used	**69,019**	61,766
Depreciation and amortisation	**46,761**	53,450
Professional and technical service fee	**22,663**	10,067
Traveling and transportation expenses	**9,068**	4,575
Utilities	**5,878**	10,535
Others	**5,091**	12,355
Total	**583,881**	612,718

7. Other Income – Net

Other income – net primarily consists of government grants and net fair value gains on contingent consideration payable to AB Studio Inc. ("**ABS**"). Government grants amounted to RMB4.9 million and RMB19.2 million in 2022 and 2021, separately. Net fair value gains on contingent consideration payable to ABS decreased from RMB25.3 million in 2021 to RMB4.9 million in 2022.

8. Finance Income and Costs

Finance income increased from RMB23.7 million in 2021 to RMB53.3 million in 2022, primarily due to the net foreign currency exchange gains in 2022.

Finance costs decreased from RMB30.9 million in 2021 to RMB3.0 million in 2022, primarily due to the net foreign currency exchange losses in 2021 and the net foreign currency exchange gains in 2022.

9. Loss for the Reporting Period

As a result of the foregoing, our losses decreased from RMB865.4 million in 2021 to RMB730.4 million in 2022.

10. Liquidity and Source of Funding and Borrowing

Our management monitors and maintains a level of cash and bank balances deemed adequate to finance our operations and mitigate the effects of fluctuations in cash flow. We rely on equity financing as the major source of liquidity. Historically, we had borrowed loans from related parties and bank. As at 31 December 2022, the short-term borrowings from bank were nil (as at 31 December 2021: RMB29.7 million).

As at 31 December 2022, our cash and bank balances decreased to RMB1,588.7 million from RMB2,200.6 million as at 31 December 2021. The decrease was mainly due to the operating loss in 2022.

11. Non-HKFRS Measure

To supplement the Group's consolidated financial statements which are prepared in accordance with the HKFRS, the Company also uses adjusted loss as an additional financial measure, which is not required by, or presented in accordance with HKFRS. The Company believes that this non-HKFRS financial measure is useful for understanding and assessing underlying business performance and operating trends. The Company also believes that the Company's management and investors may benefit from referring to this non-HKFRS financial measure in assessing the Group's financial performance by eliminating the impact of certain items that the Group does not consider indicative of the performance of the Group's business. However, the presentation of this non-HKFRS financial measure is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with HKFRS. The use of this non-HKFRS measure has limitations as an analytical tool, and investors should not view the non-HKFRS financial results on a stand-alone basis or as a substitute for results under HKFRS, or as being comparable to results reported or forecasted by other companies.

The following table reconciles our Adjusted Loss for the Reporting Period to the most directly comparable financial measure calculated and presented in accordance with HKFRS:

	Year ended 31 December	
	2022	2021
	RMB'000	*RMB'000*
HKFRS Loss for the year	**(730,396)**	(865,374)
Add:		
Share-based payment expenses	**48,238**	134,273
Adjusted Loss for the year	**(682,158)**	(731,101)

12. Key Financial Ratios

The following table sets forth the key financial ratios for the details indicated:

	As at 31 December 2022	As at 31 December 2021
Current ratio[1]	**6.61**	7.62
Quick ratio[2]	**6.24**	7.17
Gearing ratio[3]	**0.15**	0.13

Notes:

1. Current ratio is calculated using current assets divided by current liabilities as at the same date.

2. Quick ratio is calculated using current assets less inventories and prepayments and divided by current liabilities as at the same date.

3. Gearing ratio is calculated using total liabilities divided by total assets as at the same date.

13. Significant Investments

The Group did not make or hold any significant investments (including any investment in an investee company with a value of 5 per cent or more of the Company's total assets as at 31 December 2022) during the Reporting Period.

14. Material Acquisitions and Disposals

The Group did not have any material acquisitions or disposals of subsidiaries, consolidated affiliated entities or associated companies during the Reporting Period (for the year ended 31 December 2021: nil).

15. Pledge of Assets

As at 31 December 2022, none of the Group's assets were pledged (as at 31 December 2021: nil).

16. Contingent Liabilities

As at 31 December 2022, the Group had no significant contingent liabilities (as at 31 December 2021: nil).

17. Foreign Exchange Exposure

During the Reporting Period, we operated in the People's Republic of China (the "**PRC**") with most of the transactions settled in Renminbi. Our presentation and functional currency is Renminbi. We were not exposed to significant foreign exchange risk as there were no significant financial assets or liabilities of us denominated in the currencies other than Renminbi, except for the cash at bank in U.S. Dollar ("**USD**") which were primarily received from the investors as capital contributions and the proceeds obtained from the IPO.

As at 31 December 2022, if RMB weakened or strengthened by 10% against USD, with all other variables held constant, loss for the year of the Group would have been approximately RMB22,555,000 lower or higher (2021: RMB35,851,000 lower or higher).

We did not use any derivative contracts to hedge against our exposure to currency risk during the Reporting Period. However, our management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

18. Employees and Remuneration

As at 31 December 2022, the Group had a total of 264 employees including 166 employees in Shanghai, 93 employees in Yuxi, Yunnan, 2 employees in Hong Kong and 3 employees in San Francisco, United States. The following table sets forth the total number of employees by function as at 31 December 2022:

	Number of employees	% of total
Function		
Research and Development	75	28.4%
Clinical Development	57	21.6%
General and Administration	39	14.8%
Manufacturing	93	35.2%
Total	**264**	**100%**

The total remuneration cost incurred by the Group for the Reporting Period was RMB333.0 million, as compared to RMB444.7 million for the year ended 31 December 2021.

Our employees' remuneration comprises salaries, bonuses, share-based payment expenses, social security contributions and other welfare payments. In accordance with applicable Chinese laws, we have made contributions to social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds for our employees. As at 31 December 2022, we had complied with all statutory social security insurance fund and housing fund obligations applicable to us under Chinese laws in all material aspects.

The Company also has adopted a Pre-IPO share option plan (the "**Pre-IPO Share Option Plan**"), a post-IPO share option plan (the "**Post-IPO Share Option Plan**") and a 2021 restricted share unit plan (the "**2021 RSU Plan**") to provide incentives or rewards to eligible participants for their contribution to the Group. Please refer to the section headed "Statutory and General Information – D. Share Option Schemes" in Appendix IV to the prospectus of the Company dated 23 September 2020 (the "**Prospectus**") for further details of the Pre-IPO Share Option Plan and the Post-IPO Share Option Plan and the announcements of the Company dated 3 June 2021, dated 27 August 2021 and dated 5 October 2022 for further details of the 2021 RSU Plan.

FINAL DIVIDEND

The Board does not recommend the distribution of a final dividend for the Reporting Period.

ANNUAL GENERAL MEETING

The annual general meeting of the Company is scheduled to be held on Thursday, 29 June 2023 (the "**AGM**"). A notice convening the AGM will be published and dispatched to the shareholders of the Company (the "**Shareholders**") as soon as practicable in accordance with the Company's articles of association and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") (the "**Listing Rules**") in due course.

CLOSURE OF THE REGISTER OF MEMBERS

The register of members of the Company will be closed from Monday, 26 June 2023 to Thursday, 29 June 2023, both days inclusive, in order to determine the identity of the Shareholders who are entitled to attend and vote at the AGM, during which period no share transfers will be registered. To be eligible to attend and vote at the AGM, unregistered holders of shares must lodge all properly completed transfer forms accompanied by the relevant share certificates with the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. on Friday, 23 June 2023.

CORPORATE GOVERNANCE AND OTHER INFORMATION

The Company was incorporated under the laws of the Cayman Islands on 10 April 2017 as an exempted company with limited liability, and the shares of the Company were listed on the Stock Exchange on 7 October 2020.

1. Compliance with the Corporate Governance Code

The Board is committed to establishing and maintaining high standards of corporate governance so as to enhance corporate transparency and protect the interests of the Shareholders. The Company devotes to best practice on corporate governance, and to comply with the extent practicable, with the Corporate Governance Code (the "**CG Code**") as set out in Appendix 14 of the Listing Rules.

During the year ended 31 December 2022, to the best knowledge of the Board, the Company has complied with all the code provisions in the CG Code, save for deviation from code provision C.2.1 as explained below:

Pursuant to code provision C.2.1 of the CG Code, the roles of chairman and chief executive officer should be separated and should not be performed by the same individual. The division of responsibilities between the chairman and chief executive should be clearly established and set out in writing.

Dr. GUO Feng ("**Dr. Guo**") performs both of the roles as the chairman and the chief executive of the Company with effect from 2 November 2021. This deviates from code provision C.2.1 of the CG Code which requires that the roles of chairman and chief executive should be separated and should not be performed by the same individual.

After evaluation of the current situation of the Company and taking into account of the experience and past performance of Dr. Guo, the Board is of the opinion that it is appropriate and in the best interests of the Company at the present stage for Dr. Guo to hold both positions as the chairman and the chief executive officer of the Company as it helps to facilitate the execution of the Group's business strategies and boost effectiveness of its operation. In addition, the Board, comprising of one executive Director, three non-executive Directors and three independent non-executive Directors, is appropriately structured with balance of power to provide sufficient checks to protect the interests of the Company and the Shareholders.

Further information concerning the corporate governance practices of the Company will be set out in the corporate governance report in the annual report of the Company for the Reporting Period.

The Company will continue to regularly review and monitor its corporate governance practices to ensure compliance with the CG Code, and to maintain a high standard of corporate governance practices of the Company.

2. Compliance with the Model Code for Securities Transactions by Directors

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix 10 to the Listing Rules (the "**Model Code**") to regulate all dealings by Directors and relevant employees in securities of the Company and other matters covered by the Model Code.

Specific enquiry has been made to all the Directors and they have confirmed that they have complied with the required standards as set out in the Model Code throughout the Reporting Period. No incident of non-compliance of the Model Code by the relevant employees was noted by the Company throughout the Reporting Period.

3. Scope of Work of PricewaterhouseCoopers

The figures in respect of this announcement of the Group's results for the Reporting Period have been agreed by the Group's auditor, PricewaterhouseCoopers, to the amounts set out in the Group's audited consolidated financial statements for the Reporting Period. The work performed by PricewaterhouseCoopers in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently no assurance has been expressed by PricewaterhouseCoopers on this announcement.

4. Review of Consolidated Annual Results by the Audit Committee

The Company has established an audit committee with written terms of reference in accordance with the Listing Rules. The audit committee comprises three members, namely Mr. FUNG Edwin, Mr. LIU Yi and Mr. ZHOU Honghao, with Mr. FUNG Edwin (being the Company's independent non-executive Director with appropriate professional qualifications) as the chairman of the audit committee.

The audit committee has reviewed the audited consolidated financial statements of the Group for the Reporting Period and has met with the independent auditor, PricewaterhouseCoopers. The audit committee has also discussed matters with respect to the accounting policies and practices adopted by the Company and internal control, risk management and financial reporting matters with senior management members of the Company. The audit committee is satisfied that the audited consolidated financial statements of the Group for the Reporting Period were prepared in accordance with the applicable accounting standards and fairly present the Group's financial position and results for the Reporting Period.

5. Other Board Committees

In addition to the audit committee, the Company has also established a nomination committee and a compensation committee.

6. Purchase, Sale or Redemption of the Company's Listed Securities

During the Reporting Period, the Company repurchased a total of 1,417,000 Shares on the Stock Exchange for an aggregate consideration of HK$5,999,755. All of the Shares repurchased were cancelled on 26 July 2022.

Details of the Shares repurchased during the period are as follows:

Month	Number of Shares repurchased	Purchase price per share		Aggregate consideration
		Highest *(HK$)*	Lowest *(HK$)*	*(HK$)*
June 2022	1,344,000	4.39	3.86	5,710,955
July 2022	73,000	4.22	3.81	288,800
Total	1,417,000			5,999,755

Save as disclosed above, neither the Company nor any of its subsidiaries or consolidated affiliated entities purchased, sold or redeemed any of the Company's listing securities during the Reporting Period.

7. Material Litigation

The Company was not involved in any material litigation or arbitration during the Reporting Period. The Directors are also not aware of any material litigation or claims that are pending or threatened against the Group during the Reporting Period and up to the date of this announcement.

8. Use of Net Proceeds from Global Offering

The Company's shares were listed on the Stock Exchange on 7 October 2020 with a total of 129,683,500 offer shares (including shares issued as a result of the partial exercise of the over-allotment option) issued and the net proceeds raised during the global offering were approximately HK$2,923 million. The net proceeds from the global offering were allocated and used in accordance with the use of proceeds as set out in the Prospectus and the change in use of proceeds from the global offering allocated to different stages of each of our Core Products, other key products and other pipeline products as set out in the interim results announcement of the Company for the six months ended 30 June 2022 (the "**2022 Interim Results Announcement**").

The unutilised net proceeds are approximately RMB1,179.4 million as at 31 December 2022, which will be allocated and used in accordance with the purposes and proportions as set out in the Prospectus and the 2022 Interim Results Announcement. The Company will gradually utilise the residual amount of the net proceeds in accordance with such intended purposes depending on actual business needs.

As at 31 December 2022, details of the proceeds that have been used and will continue to be used in accordance with those set out in the Prospectus and the adjustment in the 2022 Interim Results Announcement are set out below:

	Allocation of net proceeds from the global offering in the proportion disclosed in the Prospectus *(Note 1)* *RMB million*	**Utilisation as at 31 December 2022** *RMB million*	**Unutilised as at 31 December 2022** *RMB million*	**Expected timeline to fully utilise the remaining unutilised net proceeds** *(Note 2)*
Fund research and development activities of our Core Products, including ongoing and planned clinical trials, indication expansion and preparation for registration filings, and commercialisation	1,065.1	570.6	494.5	On or before 31 December 2025
Fund research and development activities of our other key products, including ongoing and planned clinical trials, indication expansion and preparation for registration filings	583.3	396.8	186.5	On or before 31 December 2025
Fund ongoing and planned clinical trials, indication expansion and preparation for registration filings of the other drug candidates in our pipeline	380.4	139.8	240.6	On or before 31 December 2025
Fund the expansion of our drug pipeline	253.6	73.5	180.1	On or before 31 December 2025
General corporate purposes	253.6	175.9	77.7	On or before 31 December 2024
Total	**2,536.0**	**1,356.6**	**1,179.4**	

Notes:

1. The net proceeds include the additional net proceeds from the partial exercise of the over-allotment option. As set out in the Company's announcement dated 28 October 2020, the Company shall utilise the additional net proceeds on a pro-rata basis for the purposes set out in the Prospectus. The net proceeds figure has been translated to Renminbi for the allocation and the utilisation calculation, and has been adjusted slightly due to the fluctuation of the foreign exchange rates since the Listing.

2. The expected timeline for fully utilising the remaining unutilised net proceeds is based on the best estimation of the future market conditions made by the Group. It will be subject to change based on the current and future development of market conditions.

The table below specifies the further breakdown for the revised net proceeds to be allocated to different stages of each of our Core Products (has the meaning ascribed to it under Chapter 18A of the Listing Rules), other key products and other pipeline products as stated in the 2022 Interim Results Announcement and their planned application and actual utilisation as as at 31 December 2022:

	Revised Net Proceeds to be Allocated to Each Stage as stated in the 2022 Interim Results Announcement [Note 3]					
	Pre-clinical *RMB million*	**Clinical** *RMB million*	**Commercialisation (including registration)** *RMB million*	**Utilisation as at 31 December 2022** *RMB million*	**Unutilised as at 31 December 2022** *RMB million*	**Expected timeline to fully utilise the remaining unutilised net proceeds** [Note 4]
Core Products						
GB226, including combination trials with GB492	–	380.4	253.6	339.7	294.3	On or before 31 December 2025
GB221	–	126.8	126.8	126.8	126.8	On or before 31 December 2025
GB242	–	51.5	126.0	104.1	73.4	On or before 31 December 2024
Other Key Products						
GB491	–	576.1	–	389.6	186.5	On or before 31 December 2024
GB223	–	7.2	–	7.2	–	
Other Pipeline Products						
(including GB261, GB263 and other products) [Note5]	125.5	254.9	–	139.8	240.6	On or before 31 December 2025
Total				**1,107.2**	**921.6**	

Notes:

3. The net proceeds include the additional net proceeds from the partial exercise of the over-allotment option. The net proceeds figure has been translated to Renminbi for the allocation and the utilisation calculation, and has been adjusted slightly due to the fluctuation of the foreign exchange rates since the Listing. As set out in the Company's announcement dated 28 October 2020 and the 2022 Interim Results Announcement, the Company shall utilise the additional net proceeds according to the revised allocation based on the purposes set out in the Prospectus.

4. The expected timeline for fully utilising the remaining unutilised net proceeds is based on the best estimation of the future market conditions made by the Group. It will be subject to change based on the current and future development of market conditions.

5. As set out in the Prospectus and the 2022 Interim Results Announcement, other products include GB241, GB222, GB224, GB235, GB251, GB232, GB262, GB264, and also GB223 moved from other key products. The Company will make investment on those products according to the current and future development conditions and market competition environment.

CONSOLIDATED FINANCIAL STATEMENTS

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	Notes	Year ended 31 December	
		2022	2021
		RMB'000	*RMB'000*
Revenue	3	**15,932**	–
Cost of revenue		**(983)**	–
Gross profit		**14,949**	–
Selling expenses		**(83,143)**	(98,603)
Administrative expenses		**(134,130)**	(207,350)
Research and development expenses		**(583,881)**	(612,718)
Other income – net		**9,855**	44,813
Other (losses)/gains – net		**(6,369)**	14,751
Operating loss		**(782,719)**	(859,107)
Finance income		**53,314**	23,729
Finance costs		**(3,015)**	(30,928)
Finance income/(costs) – net		**50,299**	(7,199)
Loss before income tax		**(732,420)**	(866,306)
Income tax credit	4	**2,024**	932
Loss for the year		**(730,396)**	(865,374)
Loss for the year is attributable to:			
Owners of the Company		**(730,214)**	(865,224)
Non-controlling interests		**(182)**	(150)
Other comprehensive loss			
Items that may be reclassified to profit or loss			
– Exchange differences on translation of foreign operations		**(1,389)**	(465)
Total comprehensive loss for the year		**(731,785)**	(865,839)
Total comprehensive loss for the year is attributable to:			
Owners of the Company		**(731,603)**	(865,689)
Non-controlling interests		**(182)**	(150)
Loss per share attributable to the ordinary equity holders of the Company			
Basic loss per share (in RMB)	5	**(1.45)**	(1.75)
Diluted loss per share (in RMB)	5	**(1.45)**	(1.77)

CONSOLIDATED BALANCE SHEET

	As at 31 December	
	2022	2021
	RMB'000	*RMB'000*
ASSETS		
Non-current assets		
Property, plant and equipment	**179,990**	200,033
Right-of-use assets	**25,227**	23,334
Intangible assets	**163,208**	171,043
Other receivables, deposits and prepayments	**19,600**	76,121
Deferred income tax assets	**6,913**	5,732
Total non-current assets	**394,938**	476,263
Current assets		
Inventories	**47,404**	49,653
Contract cost	**1,341**	1,755
Other receivables, deposits and prepayments	**82,703**	132,529
Restricted bank deposits	**–**	2,000
Cash and bank balances	**1,588,705**	2,200,641
Total current assets	**1,720,153**	2,386,578
Total assets	**2,115,091**	2,862,841

CONSOLIDATED BALANCE SHEET (CONTINUED)

	Notes	As at 31 December 2022 RMB'000	2021 RMB'000
EQUITY			
Equity attributable to the ordinary equity holders of the Company			
Share capital		**69**	68
Share premium		**9,375,785**	9,290,903
Treasury shares		**(5,198)**	(5,198)
Other reserves		**(1,452,204)**	(1,409,824)
Accumulated losses		**(6,115,974)**	(5,385,760)
		1,802,478	2,490,189
Non-controlling interests		**2,740**	2,922
Total equity		**1,805,218**	2,493,111
LIABILITIES			
Non-current liabilities			
Lease liabilities		**21,823**	20,107
Amounts due to related parties		**1,232**	5,004
Deferred income		**13,984**	18,149
Deferred income tax liabilities		**12,439**	13,282
Total non-current liabilities		**49,478**	56,542
Current liabilities			
Trade payables	6	**132,158**	129,666
Contract liabilities		**4,893**	5,648
Other payables and accruals		**109,643**	124,930
Short-term borrowings		**–**	29,700
Lease liabilities		**6,763**	7,601
Amounts due to related parties		**1,360**	4,056
Provisions		**1,886**	7,895
Deferred income		**3,692**	3,692
Total current liabilities		**260,395**	313,188
Total liabilities		**309,873**	369,730
Total equity and liabilities		**2,115,091**	2,862,841

NOTES TO THE CONSOLIDATED FINANCIAL INFORMATION

1 GENERAL INFORMATION

1.1 General information

Genor Biopharma Holdings Limited (the "**Company**"), previously known as JHBP (CY) Holdings Limited, and its subsidiaries (together the "**Group**"), have principally engaged in developing and commercializing oncology and autoimmune drugs in the People's Republic of China (the "**PRC**").

The Company was incorporated in the Cayman Islands on 10 April 2017 as an exempted company with limited liability under the Companies Law (Cap.22, Law 3 of 1961 as consolidated and revised) of the Cayman Islands. The address of the Company's registered office is Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.

The Company has its primary listing on The Stock Exchange of Hong Kong Limited.

These financial statements are presented in Renminbi ("**RMB**"), unless otherwise stated.

Following the outbreak of Coronavirus Disease 2019 in early 2020 and the Omicron variant in 2022 (together, the "**COVID-19 pandemic**"), a series of precautionary and control measures had been implemented across the country in this year. As at the reporting date, the Group was not aware of any material adverse effects on the financial statements as a result of the COVID-19 pandemic.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This note provides a list of the significant accounting policies adopted in the preparation of these consolidated financial statements. These policies have been consistently applied to all the years presented, unless otherwise stated. The financial statements are for the Group consisting of Genor Biopharma Holdings Limited and its subsidiaries.

2.1 Basis of preparation

(a) Compliance with HKFRS and the disclosure requirements of HKCO

The consolidated financial statements of the Group have been prepared in accordance with Hong Kong Financial Reporting Standards ("**HKFRS**") and the disclosure requirements of the Hong Kong Companies Ordinance Cap. 622.

(b) Historical cost convention

The financial statements have been prepared on a historical cost basis, except for certain financial assets and liabilities measured at fair value.

(c) New and amended standards adopted by the Group

The Group has applied the following amendments or annual improvements for the first time for their annual reporting period commencing 1 January 2022:

- Property, Plant and Equipment: Proceeds before Intended Use – Amendments to HKAS 16
- Onerous Contracts – Cost of Fulfilling a Contract – Amendments to HKAS 37
- Annual Improvements to HKFRS Standards 2018-2020
- Reference to the Conceptual Framework – Amendments to HKFRS 3
- Covid-19 Related Rent Concessions beyond 30 June 2021 – Amendment to HKFRS 16 (March 2021), and
- Amendments to AG 5 Merger Accounting for Common Control Combinations

The Group did not change its accounting policies or make retrospective adjustments as a result of adopting the abovementioned amended standards or annual improvements.

(d) New standards and interpretations not yet adopted

		Effective for annual periods beginning on or after
• HKFRS 17	Insurance Contracts	01-Jan-23
• HKFRS 17	Amendments to HKFRS 17	01-Jan-23
• HKFRS 17	Initial Application of HKFRS 17 and HKFRS 9 – Comparative Information	01-Jan-23
• Amendments to HKAS 1 and HKFRS Practice Statement 2	Disclosure of Accounting Policies	01-Jan-23
• Amendments to HKAS 8	Definition of Accounting Estimates	01-Jan-23
• Amendments to HKAS 12	Deferred Tax related to Assets and Liabilities arising from a Single Transaction	01-Jan-23
• Hong Kong Interpretations 5 (Revised)	Presentation of financial statements – classification by the borrower of a term loan that contains a repayment on demand clause	01-Jan-24
• Amendments to HKAS 1	Classification of Liabilities as Current or Non-current	01-Jan-24
• Amendments to HKAS 1	Non-current Liabilities with Covenants (amendments)	01-Jan-24
• Amendments to HKFRS 16	Lease liability in a sale and leaseback	01-Jan-24
• Amendments to HKFRS 10 and HKAS 28	Sale or contribution of assets between an investor and its associate or joint venture	To be determined

Certain new accounting standards, amendments to accounting standards and interpretations have been published that are not mandatory for 31 December 2022 reporting periods and have not been early adopted by the Group. These standards, amendments or interpretations are not expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.

3 REVENUE

	Year ended 31 December	
	2022	2021
	RMB'000	*RMB'000*
Timing of revenue recognition		
At a point in time:		
– Sales of goods	**11,880**	**–**
– Fee for service contracts	**4,052**	**–**
	15,932	**–**

(a) Information about major customers

Revenue from customers contributing over 10% of the total revenue of the Group is as follows:

	Year ended 31 December	
	2022	2021
	RMB'000	*RMB'000*
Customer A	**5,878**	**–**
Customer B	**3,125**	**–**
Customer C	**2,701**	**–**
Customer D	**2,101**	**–**
	13,805	**–**

The amount of revenue from external customers broken down by location of the customers is shown in the table below.

	Year ended 31 December	
	2022	2021
	RMB'000	*RMB'000*
Mainland China	**12,807**	**–**
United States of America ("**USA**")	**3,125**	**–**
	15,932	**–**

4 INCOME TAX CREDIT

(a) Income tax credit

	Year ended 31 December	
	2022	2021
	RMB'000	*RMB'000*
Current tax		
Current tax on profits for the year	**–**	–
Total current tax expense	**–**	–
Deferred income tax		
Increase in deferred tax assets	**(1,181)**	(89)
Decrease in deferred tax liabilities	**(843)**	(843)
Total deferred tax credit	**(2,024)**	(932)
Income tax credit	**(2,024)**	(932)

(b) Numerical reconciliation of loss before income tax to income tax credit

	Year ended 31 December	
	2022	2021
	RMB'000	*RMB'000*
Loss before income tax	**(732,420)**	(866,306)
Calculated at the PRC taxation rate of 25%	**(183,105)**	(216,577)
Effect of different tax rates of operating entities in other jurisdictions	**9,903**	13,436
Effect of preferential tax rates	**59,164**	–
Expenses not deductible for taxation purposes		
– Share-based payment expenses	**6,920**	30,584
– Others	**1,722**	3,600
Super deduction of research and development expenses	**(62,025)**	(91,750)
Unused tax loss not recognised as deferred tax assets	**165,397**	259,775
Income tax credit	**(2,024)**	(932)

(i) Cayman Islands income tax

The Company is incorporated in the Cayman Islands as an exempted company with limited liability under the Companies Law of Cayman Islands and accordingly is exempted from Cayman Islands income tax.

(ii) Hong Kong Profits Tax

Hong Kong profits tax rate is 16.5% for the year ended 31 December 2022 (2021: 16.5%). No Hong Kong profit tax was provided for as there was no estimated assessable profit that was subject to Hong Kong profits tax for the years ended 31 December 2022 and 2021.

(iii) USA Corporate Income Tax

The corporate income tax rate of AB Therapeutics Inc. and Genor Biopharma (USA), Inc. are subject to both federal income tax rate and California income tax rate, which is 29.84% in total for the year ended 31 December 2022 (2021: 29.84%). No USA profit tax was provided for as there was no estimated assessable profit that was subject to USA profits tax for the years ended 31 December 2022 and 2021.

(iv) PRC Corporate Income Tax

In 2022, a "Certificate of New Hi-tech Enterprise" was granted to Genor Biopharma Co., Litd. with a valid period of 3 years, and then Genor Biopharma Co., Litd. becomes eligible for a preferential corporate income tax rate of 15% for the year ended 31 December 2022 (2021: 25%).

Other subsidiaries established and operated in Mainland China are subject to the PRC corporate income tax at the rate of 25% for the year ended 31 December 2022 (2021: 25%).

(v) Australian Corporate Income Tax

Australian corporate tax rate is 25% for the year ended 31 December 2022. No Australian corporate tax was provided for as there was no estimated assessable profit that was subject to Australian corporate tax for the year ended 31 December 2022.

5 LOSS PER SHARE

(a) Basic loss per share

Basic loss per share is calculated by dividing the loss attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the financial year.

	Year ended 31 December	
	2022	2021
Loss attributable to owners of the Company (in RMB'000)	**(730,214)**	(865,224)
Weighted average number of ordinary shares in issue (in thousand)	**504,301**	495,180
Basic loss per share (in RMB)	**(1.45)**	(1.75)

(b) Diluted loss per share

Diluted loss per share adjusts the figures used in the determination of basic loss per share to take into account:

- the after-income tax effect of fair value changes with dilutive potential ordinary shares, and
- the weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares.

The Group has potential dilutive shares throughout for the year ended 31 December 2022 related to the shares held for employee option plan and shares to be issued to an employee and ABS.

The loss attributable to the owners of the Company (the "**numerator**") has been adjusted by the effect of fair value changes on the contingent consideration to ABS, excluding those which have anti-dilutive effect to the Group's diluted loss per share.

In addition, diluted loss per share is calculated by adjusting the weighted average number of ordinary shares outstanding by the assumption of the conversion of potential dilutive ordinary shares arising from shares to be issued to ABS.

	Year ended 31 December	
	2022	2021
Loss attributable to owners of the Company (in RMB'000)		
Used in calculating basic loss per share	**(730,214)**	(865,224)
Less: the fair value gains on contingent consideration to ABS	**998**	11,278
Loss attributable to owners of the Company for the calculation of diluted loss per share	**(731,212)**	(876,502)
Weighted average number of ordinary shares used as the denominator in calculating basic loss per share (in thousand)	**504,301**	495,180
Adjustments for calculation of diluted loss per share:		
Shares to be issued to ABS	**511**	1,023
Weighted average number of ordinary shares in issue for the calculation of diluted loss per share	**504,812**	496,203
Diluted loss per share (in RMB)	**(1.45)**	(1.77)

6 TRADE PAYABLES

The aging analysis, based on invoice date, of trade payables as at the consolidated statements of balance sheet date were as follows:

	As at 31 December	
	2022	2021
	RMB'000	*RMB'000*
Within 1 year	**130,964**	127,594
1-2 years	**397**	1,772
2-3 years	**797**	300
	132,158	129,666

The carrying amounts of trade payables are denominated in RMB. The carrying amounts approximate their fair values due to short-term maturities.

7 DIVIDEND

No dividend has been paid or declared by the Company during the years ended 31 December 2022 and 2021.

PUBLICATION OF THE ANNUAL RESULTS ANNOUNCEMENT AND ANNUAL REPORT

This announcement is published on the website of the Stock Exchange at www.hkexnews.hk and the website of the Company at www.genorbio.com. The annual report of the Company for the Reporting Period will be published on the aforesaid websites and dispatched to the Shareholders in due course.

By order of the Board
Genor Biopharma Holdings Limited
Dr. Guo Feng
Chief Executive Officer and Chairman

Hong Kong, 30 March 2023

As at the date of this announcement, the Board comprises Dr. GUO Feng as executive Director; Dr. LYU Dong, Mr. CHEN Yu and Mr. LIU Yi as non-executive Directors; Mr. ZHOU Honghao, Mr. FUNG Edwin and Mr. CHEN Wen as the independent non-executive Directors.